| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | Interleukin-6 receptor subunit beta, IL-6R-beta, IL-6RB, Interleukin-6 signal transducer, Oncostatin-M receptor subunit alpha, CD130, Il6st |
| Clonality | |
| Conjugate | |
| Host | |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
Overview
Anti-GP130 (extracellular) Antibody is an antibody targeting Interleukin-6 receptor subunit beta, IL-6R-beta, IL-6RB, Interleukin-6 signal transducer, Oncostatin-M receptor subunit alpha, CD130, Il6st Polyclonal raised in Rabbit (Unconjugated). This antibody is commonly used in IFC, IHC, WB to detect, localize, or compare expression of the target across samples.
Key elements and design rationale
- Target: Interleukin-6 receptor subunit beta, IL-6R-beta, IL-6RB, Interleukin-6 signal transducer, Oncostatin-M receptor subunit alpha, CD130, Il6st (also reported as Interleukin-6 receptor subunit beta, IL-6R-beta, IL-6RB, Interleukin-6 signal transducer, Oncostatin-M receptor subunit alpha, CD130, Il6st).
- Immunogen/epitope region: Extracellular, N-terminus.
- Homology note: Mouse, human - 13/15 amino acid residues identical (informative for cross-species interpretation).
- Species reactivity (as provided): Human, Rat, Mouse.
- Lot quality control (as provided): Western blot analysis.
- Peptide confirmation: Confirmed by amino acid analysis and mass spectrometry.
- Blocking peptide: Available for antigen preadsorption control where appropriate.
- Conjugate/format: Unconjugated (may affect detection channel and background).
These attributes help researchers interpret whether signal reflects the intended target in a given assay and sample context.
Biological background
Interleukins (ILs) are key mediators in the regulation and coordination of the immune response. Glycoprotein 130 (gp130) belongs to the family of class I cytokine receptors and is the common signal transducing receptor subunit of the IL-6-type cytokines: IL-6, IL-11, leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), oncostatin M (OSM), and cardiotrophin-11.The inflammatory cytokines IL-6 and IL-11 induce gp130 homodimerization after binding to their specific α receptors, which leads to the activation of the Janus kinase/STAT signal transduction pathway2. Gp130 Heterodimerizes with LIFR in response to LIF, CNTF, OSM, or CT13.The extracellular part of gp130 contains an Ig-like domain (D1) followed by single cytokine binding module (CBM) (D2 and D3) and three fibronectin type III-like (FNIII) domains (D4, D5, and D6)3.Gp130 mRNA is ubiquitously expressed in the human body, exhibiting highest levels in saphenous vein, pericardium, ovary, omental adipose tissue, peritoneum, spleen lymph nodes, and trigeminal ganglia4.Dysregulation of gp130 expression, activation, or associated signaling pathways are implicated in a variety of human diseases including cancer, rheumatoid arthritis, Castleman's disease, cardiac myxoma, Crohn's disease, psoriasis, asthma, amyotrophic lateral sclerosis (CNTF), diabetes, atherosclerosis, systemic lupus, obesity, and postmenopausal osteoporosis5.
Research relevance and current trends
- Profiling immune-marker expression across cell subsets with single-cell or flow-based readouts.
- Connecting receptor/ligand levels to activation state and cytokine programs.
- Applying genetic perturbation or orthogonal assays to support specificity and interpretation.
Common research applications
- Western blot (WB): compare target abundance/size across lysates and conditions; consider isoforms/PTMs.
- Immunohistochemistry (IHC): examine spatial distribution in tissue and relate signal to cell-type composition.
- Immunofluorescence/ICC: assess subcellular localization and co-localization with markers in cells or sections.
- Flow cytometry (direct/indirect): quantify target-positive populations and shifts in expression across subsets.
Interpretation typically benefits from comparing matched sample sets (e.g., treated vs control, WT vs KO/KD) and using orthogonal readouts where feasible.
Notes for experimental interpretation
- Isoforms and post-translational modifications can shift apparent molecular weight or epitope accessibility across samples.
- Cross-species signal may depend on epitope conservation; consult the provided homology note when selecting models.
- Permeabilization, fixation, and antigen retrieval can change accessibility of intracellular vs extracellular epitopes.
- Conceptual control: antigen preadsorption (blocking peptide) can help assess signal dependence on the immunogen region.
- Provided control suggestions: Negative control: BLP-LR023.
- Application notes: see product-specific dilution/usage notes and control concepts provided in the dataset.
Application abbreviations: CBE- Cell-based ELISA, FC- Flow cytometry, ICC- Immunocytochemistry, IE- Indirect ELISA, IF- Immunofluorescence, IFC- Indirect flow cytometry, IHC- Immunohistochemistry, IP- Immunoprecipitation, LCI- Live cell imaging, N- Neutralization, WB- Western blot. Species abbreviations: H- Human, M- Mouse, R- Rat.
Recommended controls: Blocking peptide: BLP-LR023; Negative control: BLP-LR023.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
